Physician profile
James C Wiley
NPI 1902896004
$43,923.01
in general payments reported to CMS, 2019-2025
13 companies · $3,191 in 2025
The $3,191 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,547 · 2021: $5,299 · 2022: $1,373 · 2023: $1,399 · 2024: $6,576 · 2025: $3,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,300 · Food and Beverage: $3,976 · Travel and Lodging: $479 · Consulting Fee: $280 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,300.00 |
| Food and Beverage | $3,975.86 |
| Travel and Lodging | $478.69 |
| Consulting Fee | $280.00 |
| Education | $130.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $22,279.80 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Ironshore Pharmaceuticals INC. | $12,776.33 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $4,598.71 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $1,873.50 | 2021-2025 | Azstarys, Azstarys |
| Neos Therapeutics, LP | $1,251.86 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Adlon Therapeutics L.P. | $326.90 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.71 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $222.09 | 2025 | Jornay Pm |
| Shire North American Group INC | $177.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $141.68 | 2019-2025 | Relexxii |
| Rhodes Pharmaceuticals L.P. | $27.68 | 2019 | |
| Noven Therapeutics, LLC | $18.99 | 2024 | Xelstrym |
| Aytu Biopharma, INC. | $4.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.